Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients

Documenti analoghi

• The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
  di: Pawlyn, Charlotte, et al.
  Pubblicazione: (2019)
• Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial
  di: Rana, Ritika, et al.
  Pubblicazione: (2020)
• Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
  di: Jackson, Graham H., et al.
  Pubblicazione: (2021)
• Subclonal TP53 copy number is associated with prognosis in multiple myeloma
  di: Shah, Vallari, et al.
  Pubblicazione: (2018)
• Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
  di: Croft, James, et al.
  Pubblicazione: (2020)